Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion) The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies CHENGDU, CHINA, February 23, 2021—Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines …
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing Read More »